BACKGROUND: Randomized controlled trial data for non-histaminergic normal C1 inhibitor (nC1INH) angioedema prevention are lacking.
METHODS: Patients aged ≥12 years with investigator-confirmed non-histaminergic nC1INH angioedema were enrolled in phase III, multicenter, randomized, placebo-controlled, double-blind CASPIAN Study (NCT04206605). Patients with ≥1 investigator-confirmed angioedema attack/4 weeks during observation period were randomized 2:1 to lanadelumab 300 mg every 2 weeks or placebo. Primary efficacy outcome was investigator-confirmed angioedema attack number during the 26-week treatment period. Safety was analyzed as treatment-emergent adverse events (TEAEs). After completing the treatment period, patients could roll over to CASPIAN open-label extension (CASPIAN OLE; NCT04444895) for an additional 26-week lanadelumab treatment to assess long-term safety and efficacy.
RESULTS: A total of 77 patients (mean ± SD age of 42.8 ± 12.9 years, 80.5% women, 88.3% White) were enrolled (lanadelumab, 50; placebo, 27). Primary efficacy outcome was not different with lanadelumab versus placebo (1.82 vs. 1.78 attacks/month; rate ratio, 1.02; p=0.90), with attack rate reduction from baseline in both groups. Subgroups meeting a clinical definition of HAE [known mutations (n=5) or family history and unknown mutations (n=13)] showed positive attack rate reduction trend with lanadelumab versus placebo. Angioedema attack rate reduction with lanadelumab was observed in CASPIAN OLE. In both studies, all treatment-related TEAEs were non-serious, and most were non-severe; most frequent treatment-related TEAEs were similar to those previously reported in lanadelumab clinical trials.
CONCLUSION: In patients with non-histaminergic nC1INH angioedema, lanadelumab safety was consistent with previous studies; efficacy remained inconclusive due to unmet CASPIAN primary endpoint. Overall results suggest potential clinical benefit in symptom control.
CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov/, identifiers NCT04206605, NCT04444895.
Primary efficacy outcome was not different with lanadelumab versus placebo (1.82 vs. 1.78 attacks/month; rate ratio, 1.02; p=0.90), with attack rate reduction from baseline in both groups.
directly identified by the blinded randomized comparison and consistent sensitivity analysis
Subgroups meeting a clinical definition of HAE showed positive attack rate reduction trend with lanadelumab versus placebo.
post-hoc analysis of only 18 participants with a non-significant rate ratio
Angioedema attack rate reduction with lanadelumab was observed in CASPIAN OLE.
single-arm open-label extension without a concurrent control cannot identify treatment causality
In patients with non-histaminergic nC1INH angioedema, lanadelumab safety was consistent with previous studies; efficacy remained inconclusive due to unmet CASPIAN primary endpoint. Overall results suggest potential clinical benefit in symptom control.
null randomized efficacy result with supportive evidence confined to small subgroups and an uncontrolled extension
Derived from the full evaluation — not a separate score.
Strengths
The study addresses a documented absence of randomized prophylaxis data for non-histaminergic normal-C1-inhibitor angioedema, making its null result a meaningful addition to a sparse evidence base.
↳ Introduction, treatment-evidence gap; Discussion, paragraph 1
CASPIAN used stratified interactive-response randomization, broad blinding, a prespecified count model, FAS analysis, sensitivity analysis, and high treatment adherence. Completion was high in both randomized groups.
↳ Methods, CASPIAN and Statistical Analysis; Results, Patient Disposition and Adherence; Table 2
The Discussion connects possible mast-cell-mediated misclassification, high placebo response, and very small hereditary subgroups directly to the null endpoint and inability to draw definitive efficacy conclusions.
↳ Discussion, diagnostic-classification paragraphs and limitations paragraph
Limitations
The idiopathic subgroup comprised 59 of 77 participants, and the paper acknowledges that antihistamine non-response may not exclude mast-cell-mediated disease. This limits what the randomized estimate establishes about bradykinin-mediated angioedema.
↳ Results, Patient Demographics; Discussion, diagnostic-complexity paragraphs
Only five participants had known mutations and thirteen had family history with unknown mutations. The numerical subgroup pattern is therefore exploratory and cannot resolve efficacy in HAE-nC1INH.
↳ Results, Patient Demographics and Primary Efficacy Endpoint; Tables 3–4
The open-label extension had no concurrent control, yet the Discussion describes its before–after reductions as demonstrating a treatment effect. Regression to the mean, time trends, and the randomized-period placebo response remain alternative explanations.
↳ Methods, CASPIAN OLE Statistical Analysis; Discussion, paragraph beginning “In CASPIAN OLE”
The randomized CASPIAN comparison was competently executed and transparently reported, with virtually identical adjusted attack rates and a sensitivity analysis that retained the null result. Contribution and context score strongly because the trial fills a genuine randomized-evidence gap and traces evolving diagnostic definitions directly to interpretation. Reporting scores lower because the Discussion’s “demonstrating a treatment effect” language is not supported by the uncontrolled extension design, even though the Abstract and Conclusion call efficacy inconclusive. The trial is therefore most useful as rigorous null evidence and as guidance for better-enriched future studies, rather than as support for treatment adoption.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Strong4.0
Confidence highThe first randomized prophylaxis trial in this population replaces an evidence base previously limited to open-label studies, reports, and consensus with an informative null result. Its ability to resolve efficacy in hereditary subgroups is limited by samples of five and thirteen participants.
“The primary endpoint did not show a significant reduction in the number of angioedema attacks with lanadelumab compared with placebo.”
The randomized period used stratified interactive-response allocation, comprehensive blinding, an adjusted count model, FAS analysis, sensitivity analysis, high adherence, and systematic harms reporting. Diagnostic heterogeneity, six retrospectively ineligible participants, and an optimistic effect-size assumption constrain design-to-population fit without invalidating the null comparison.
“A sensitivity analysis showed no notable difference”
The manuscript clearly identifies the null primary result and repeatedly calls efficacy inconclusive. Precision is reduced when the Discussion says the uncontrolled extension demonstrated a treatment effect and the Conclusion emphasizes a positive trend and potential benefit.
“demonstrating a treatment effect of lanadelumab during the open-label treatment period”
The Discussion distinguishes CASPIAN from the HELP trial and engages evolving DANCE classification, mutation panels, and omalizumab-response criteria. Diagnostic limitations are traced directly to population heterogeneity and interpretation of the null result, although alternative prophylactic evidence receives less detailed treatment.
“some of these patients may have had mast cell-mediated angioedema”
Lower confidence on Reporting — domain match limited.
Caveats4 of 4 checks
The randomized counts and primary estimates are internally consistent, but interpretation of the uncontrolled extension is causally stronger than its design supports. Eligibility deviations and baseline attack-rate imbalance are disclosed and partly addressed without changing the null randomized result.
Ethics approval, informed consent, trial registration, safety monitoring, and a specific data-access process are declared. No supplied-text conduct concern was identified.
Flags: 3 declared / 5 total
31 of 31 checkable references verified
35 references in manuscript 4 are books, websites or datasets — counted, but not index-checkable
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
A multicountry phase III randomized design places the intervention in a clinically advanced testing context. Readiness remains limited because efficacy was not demonstrated in the randomized population and the extension lacked a concurrent control.
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine
Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.
Well-supportedRiedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine
Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate
SupportedCohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine
NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.
Tentative